|
Sep 08, 2020
|
BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference
|
|
|
Sep 03, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 03, 2020
|
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
|
|
|
Aug 31, 2020
|
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
|
|
|
Aug 31, 2020
|
FDA Grants Orphan Drug Designation for BCX9930 in PNH
|
|
|
Aug 06, 2020
|
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones
|
|
|
Aug 04, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Aug 03, 2020
|
FDA Grants Fast Track Designation for BCX9930 in PNH
|
|
|
Jul 23, 2020
|
BioCryst to Report Second Quarter 2020 Financial Results on August 6
|
|
|
Jul 02, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
